SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-K: FORM 10-K For the fiscal year ended December

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 10-K, Date: 2010-03-31
Original SEC Filing: Click here


Webplus: SKBI/20100331/10-K/1/000.htm SEC Original: v179475_10k.htm
FORM 10-K For the fiscal year ended December 31, 2009 OR For the transition period from ________________ to ________________ 001-15643YSTAR BIO-PHARMACEUTICALMPANY Nevada 33-0901534 (State or other jurisdiction oforporation or organization) (I.R.S. Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China




Webplus: SKBI/20100331/10-K/6_EX-10.17/000.htm SEC Original: v179475_ex10-17.htm
SERVICESREEMENT This SERVICESREEMENT (thisreement),ted of March 30, 2010, by and betweenystar Bio-Pharmaceuticalmpany, a Nevadarporation (thempany), and R.ott Cramer, an individual, whosedress is 1012 Lewis Drive Winter Park, Florida 32789-2225 (Consultant). Thempany and thensultant arellectively referred to herein the Parties.




Webplus: SKBI/20100331/10-K/7_EX-31.1/000.htm SEC Original: v179475_ex31-1.htm
SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light




Webplus: SKBI/20100331/10-K/8_EX-31.2/000.htm SEC Original: v179475_ex31-2.htm
SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in




Webplus: SKBI/20100331/10-K/9_EX-32.1/000.htm SEC Original: v179475_ex32-1.htm
18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer March 31, 2010




Webplus: SKBI/20100331/10-K/10_EX-32.2/000.htm SEC Original: v179475_ex32-2.htm
18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer March 31, 2010




Webplus: SKBI/20100331/10-K/11_EX-99.6/000.htm SEC Original: v179475_ex99-6.htm
Contract Registration No. 20096101021102 Technicaloperationreement Name of Project:operative Research of Party A: Xian Tianxing Bio-Pharmaceutical (stamp) Party B: Fourth Military Medical University (stamp) China Place of Execution: Xian, Shaanxi Province, Chinate of Effective: September 23, 2009 Term of Validity: From September 23, 2009 to thete when the performances under the terms of thereement aremplete.



Company Information:

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 10-K, Date: 2010-03-31CIK: 0001076939, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
RM 10601, JIEZUO PLAZA, NO. 4, FENGHUI ROAD SOUTH, GAOXIN DISTRICT
XIAN PROVINCE

Home Page Forums

By | 2016-02-05T04:28:51+00:00 March 31st, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar